# Tesamorelin: research overview — getgoodpeptides > A literature summary of tesamorelin: the FDA-approved GHRH analog for HIV-associated lipodystrophy — Phase 3 trial data, visceral fat reduction, mechanism, and what is and is not supported off-label. The only FDA-approved GHRH analog — cleared for visceral fat reduction in HIV-associated lipodystrophy. Robust clinical trial evidence in that population. Everything else is off-label. ## The short version Tesamorelin is a synthetic 44-amino-acid analog of human GHRH, with one chemical modification at its N-terminus (a trans-3-hexenoic acid group) that protects it from rapid enzymatic breakdown. It binds the same GHRH receptor that sermorelin and CJC-1295 target, triggering the pituitary to release pulses of growth hormone and, downstream, raising IGF-1. Tesamorelin is the **only compound on this desk with an FDA approval**. That approval — granted in 2010 — is specifically for reducing excess abdominal fat in adults with HIV-associated lipodystrophy, a metabolic complication of antiretroviral therapy [18]. The evidence base for this indication is solid: multiple randomized controlled trials document significant visceral fat reduction [17][19][21]. A 2026 meta-analysis pooling five RCTs found a mean visceral adipose tissue reduction of 27.71 cm2 versus placebo [17]. What the approval does not cover — and this matters — is general fat loss, anti-aging, muscle building, or use in people without HIV. All such uses are off-label and investigational. This page covers what the clinical trials actually tested. ## What it is Tesamorelin acetate is a synthetic analog of GHRH(1-44)-NH2 — the full 44-amino-acid GHRH sequence, with a trans-3-hexenoic acid group conjugated to the N-terminus. This N-terminal modification provides resistance to cleavage by dipeptidyl peptidase-IV (DPP-IV), extending plasma stability compared to native GHRH. Its empirical formula (free base) is C221H366N72O67S. It is categorized as a **GHRH receptor agonist** (growth-hormone-releasing hormone analog) and, in its approved form, is supplied clinically as the acetate salt. Research-grade tesamorelin sold outside the pharmacy supply chain lacks the quality controls of the pharmaceutical product. Tesamorelin's synonyms in research contexts include TH9507, trans-3-hexenoyl-GHRH(1-44) amide, and GHRH(1-44) analogue. It should not be confused with sermorelin (GHRH 1-29, a shorter fragment) or with CJC-1295 (a tetrasubstituted hGRF(1-29) analog with different stabilizing chemistry). ## How it works Tesamorelin binds the growth hormone-releasing hormone receptor (GHRH-R) on anterior-pituitary somatotroph cells, activating the Gs/adenylyl-cyclase/cAMP/PKA cascade. This stimulates synthesis and pulsatile secretion of endogenous GH. Downstream, GH drives hepatic production of IGF-1, and together GH and IGF-1 promote lipolysis — the breakdown of stored fat — preferentially in visceral adipose tissue. Because tesamorelin works by amplifying the body's own pulsatile GH rhythm rather than by supplying exogenous GH, physiologic feedback through somatostatin and IGF-1 remains intact [17]. This mechanistic difference from direct GH injection is why clinical studies have found tesamorelin's glucose effects to be relatively modest compared to what high-dose recombinant GH produces [20]. In a study of 13 healthy men given tesamorelin at 2 mg/day for 2 weeks, mean overnight GH rose by 0.5 ug/L (P=0.004) and IGF-1 increased by 181 ug/L (P<0.0001), while neither fasting glucose nor insulin-stimulated glucose uptake was significantly affected [20]. ## What the research shows **Meta-analysis of five RCTs in HIV-associated lipodystrophy (2026).** The most recent and comprehensive summary pooled five randomized controlled trials in HIV-positive adults with antiretroviral-related lipodystrophy. Tesamorelin reduced visceral adipose tissue by a mean of 27.71 cm2 (95% CI -38.37 to -17.06; P<0.001), trunk fat by 1.18 kg, and hepatic fat fraction by 4.28%, while lean body mass increased by 1.42 kg — all statistically significant, without serious adverse events in the pooled analysis [17]. **JAMA RCT — visceral fat and liver fat (HIV adults, n=50, 2014).** A 6-month JAMA-published randomized trial in 50 antiretroviral-treated adults with HIV found tesamorelin at 2 mg/day produced a treatment effect of -42 cm2 in visceral fat (P=0.005) and reduced hepatic lipid-to-water percentage by a net -2.9% (P=0.003) [19]. This was one of the pivotal trials documenting liver fat reduction in addition to visceral fat reduction. **52-week program — sustained effects and reaccumulation (HIV adults, 2008).** A 52-week study (n=273 tesamorelin, n=137 placebo) documented sustained visceral fat reduction of approximately 18% over the full year (P<0.001 versus baseline). Glucose parameter changes over 52 weeks were not clinically significant. Critically, upon discontinuation, visceral fat reaccumulated — benefits are contingent on continued administration [21]. **GH pulsatility and insulin sensitivity in healthy men (n=13, 2011).** In healthy men given tesamorelin at 2 mg/day for 2 weeks, mean overnight GH increased significantly and IGF-1 rose substantially, while neither fasting glucose nor insulin-stimulated glucose uptake was significantly affected — preserving the favorable glucose profile found in the HIV trials [20]. **LiverTox safety classification (NIH, 2018).** The NIH LiverTox monograph for tesamorelin assigns it a likelihood score of E (unlikely cause of clinically apparent liver injury), noting no attributable liver-injury cases have been reported and no de novo serum enzyme elevations were observed in trials [18]. **GHRH-analog class review (2025).** The Nature Reviews Endocrinology synthesis covers tesamorelin within the broader GHRH-analog pharmacology landscape, including its mechanistic rationale and clinical positioning [8]. ## Reported effects, cautions and safety Unlike the other three compounds on this desk, tesamorelin has a substantial clinical trial record in humans, so much of what can be said about effects and safety comes from controlled studies rather than community reports alone. **From clinical trials.** The most consistently documented clinical effect is significant visceral fat reduction in HIV-positive adults with lipodystrophy [17][19][21]. Lean body mass increases modestly. Hepatic fat fraction decreases. Adverse events in trials were predominantly mild: injection-site reactions, peripheral edema, and arthralgias. Glucose effects over 52 weeks were not clinically significant in the HIV trials [21], though the mechanistic concern about GH-induced insulin resistance is real and monitoring is warranted in individuals with prediabetes or dysglycemia. Active malignancy is a labeled contraindication given the GH/IGF-1 axis's mitogenic potential. **Key cautions.** The FDA approval is specific to HIV-associated lipodystrophy — generalizability to non-HIV populations wanting visceral fat reduction is mechanistically plausible but not established by large RCTs. Benefits do not persist after discontinuation: visceral fat reaccumulates within weeks of stopping [21]. Long-term oncologic safety data are limited; the 52-week trials showed no excess malignancy signal, but that window is short. Cognitive findings are mixed: one trial in older adults showed executive-function benefit [13], but a 2025 HIV cognition trial did not demonstrate significant neurocognitive improvement over standard care. Research-grade material lacks the quality assurance of the approved pharmaceutical product. Tesamorelin is prohibited in sport under WADA S2 in- and out-of-competition. ## Where it fits Tesamorelin is the most clinically grounded compound on this desk, and the only one carrying a current regulatory approval. That approval is narrow — HIV-associated lipodystrophy — and it matters that the pivotal trials were conducted in a specific population on antiretroviral therapy [17][19][21]. Extrapolating results to healthy adults seeking body composition changes, cognitive enhancement, or anti-aging effects moves well beyond the evidence base. Among the four compounds here, tesamorelin is also the most structurally complete GHRH analog: 44 amino acids versus sermorelin's 29, with N-terminal DPP-IV protection rather than CJC-1295's albumin-conjugation chemistry. This makes tesamorelin the pharmacological reference point for what a full-length, stabilized GHRH analog can achieve in terms of GH and IGF-1 stimulation, and the results are mechanistically informative for understanding the entire class [8]. --- An independent literature digest of peer-reviewed research on the GH/IGF-1 axis — organized like a clinician's briefing, not a product catalog.